---
title: "Humacyte - CW27 | 8-K: FY2025 Q3 Revenue: USD 753 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265518345.md"
datetime: "2025-11-12T12:08:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265518345.md)
  - [en](https://longbridge.com/en/news/265518345.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265518345.md)
generator: "portal-rs"
---

# Humacyte - CW27 | 8-K: FY2025 Q3 Revenue: USD 753 K

Revenue: As of FY2025 Q3, the actual value is USD 753 K.

EPS: As of FY2025 Q3, the actual value is USD -0.11.

EBIT: As of FY2025 Q3, the actual value is USD -24.39 M.

### Segment Revenue

-   Total revenue for the third quarter of 2025 was $0.8 million, with $0.7 million from U.S. sales of Symvess and $0.1 million from a research collaboration.
-   Revenue for the first nine months of 2025 was $1.6 million, with $0.9 million from U.S. sales of Symvess and $0.6 million from the research collaboration.

### Operational Metrics

-   Cost of goods sold was $0.3 million for the third quarter and $0.6 million for the first nine months of 2025.
-   Research and development expenses decreased to $17.3 million for the third quarter of 2025 from $22.9 million in the same period of 2024, and to $54.7 million for the first nine months of 2025 from $67.9 million in the same period of 2024.
-   Selling, general and administrative expenses were $7.6 million for the third quarter of 2025, up from $7.3 million in the same period of 2024, and $23.6 million for the first nine months of 2025, up from $18.4 million in the same period of 2024.
-   Net loss was $17.5 million for the third quarter of 2025, compared to $39.2 million for the same period in 2024, and $16.0 million for the first nine months of 2025, compared to $127.8 million for the same period in 2024.

### Cash Flow

-   The company reported cash, cash equivalents, and restricted cash of $19.8 million as of September 30, 2025.
-   Total net cash used in operating activities was $78.9 million for the first nine months of 2025, compared to $71.5 million for the same period in 2024.

### Unique Metrics

-   The company completed the sale of common stock and warrants resulting in net proceeds of approximately $56.5 million subsequent to September 30, 2025.

### Outlook / Guidance

-   Humacyte plans to advance the Coronary Tissue Engineered Vessel (CTEV) into a first-in-human study in CABG in 2026, with an IND application submitted to the FDA.
-   The company aims to submit a supplemental BLA for the ATEV in dialysis in the second half of 2026, subject to interim results from ongoing trials.
-   Humacyte is expanding its intellectual property estate with a new U.S. patent for its bioengineered esophagus, complementing existing patents for urinary conduits and tracheas.

### Related Stocks

- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- [Nvidia Just Delivered Bad News for AMD and Intel](https://longbridge.com/en/news/297432140.md)
- [Caisse de depot et placement du Quebec Takes $8.90 Million Position in Albemarle Corporation $ALB](https://longbridge.com/en/news/297418340.md)
- [Equitable Holdings Inc. Takes Position in TechnipFMC plc $FTI](https://longbridge.com/en/news/297418121.md)
- [Richtech Robotics Inc. $RR Shares Bought by Bank of America Corp DE](https://longbridge.com/en/news/297416593.md)
- [The Calmer Co. Details ASX Governance Compliance in Appendix 4G Filing](https://longbridge.com/en/news/297454626.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**